Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Ce...
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
patients with diffuse large B-cell lymphoma (DLBCL) when used as a monotherapy or in combination with other treatments. The EPCORE NHL-2 trial found that epcoritamab in combination with R-CHOP led to a 100% overall response rate and an 87% complete response rate in high-risk patients with previously untreated DLBCL. The EPCORE NHL-1 trial found that epcoritamab monotherapy resulted in a 59% overall response rate and a 41% complete response rate in patients with relapsed or refractory DLBCL, with 52% of complete responders still responding at three years. Media Release COPENHAGEN, Denmark; December 9, 2024 Results from Arm 1 of the EPCORE ® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in high-risk patients with previously untreated diffuse large B-cell lymphoma (DLBCL) Extended follow-up data from EPCORE ® NHL-1 trial demonstrates durability of responses and long-term
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Sanford C. Bernstein from a "strong sell" rating to a "hold" rating.MarketBeat
- Antibody Discovery Market Industry Forecast Report 2024-2035, Featuring Ablexis, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, MabSilico, Nona Biosciences, WuXi Biologics and More [Yahoo! Finance]Yahoo! Finance
- FairJourney Biologics Establishes Scientific Advisory Board [Yahoo! Finance]Yahoo! Finance
- Genmab A/S: Circling Back On This Complicated Story [Seeking Alpha]Seeking Alpha
- Genmab to Hold 2024 R&D Update and ASH Data Review Meeting [Yahoo! Finance]Yahoo! Finance